Milestone Pharmaceuticals Inc (MIST) - Total Assets
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) holds total assets worth $87.75 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Milestone Pharmaceuticals Inc - Total Assets Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see MIST market cap for the company's overall valuation and market capitalisation.
Milestone Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Milestone Pharmaceuticals Inc's total assets of $87.75 Million consist of 97.9% current assets and 2.1% non-current assets. Review Milestone Pharmaceuticals Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.5% |
| Accounts Receivable | $2.39 Million | 3.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MIST stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Milestone Pharmaceuticals Inc's current assets represent 97.9% of total assets in 2024, a decrease from 99.9% in 2017.
- Cash Position: Cash and equivalents constituted 33.5% of total assets in 2024, down from 39.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Milestone Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Milestone Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Milestone Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.24 | 15.40 | 24.14 |
| Quick Ratio | 8.24 | 15.40 | 24.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $76.15 Million | $75.73 Million | $142.53 Million |
Milestone Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Milestone Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.31 |
| Latest Market Cap to Assets Ratio | 1.04 |
| Asset Growth Rate (YoY) | 0.4% |
| Total Assets | $75.50 Million |
| Market Capitalization | $78.32 Million USD |
Valuation Analysis
Above Book Valuation: The market values Milestone Pharmaceuticals Inc's assets above their book value (1.04x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Milestone Pharmaceuticals Inc's assets grew by 0.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual total assets of Milestone Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $75.50 Million | +0.36% |
| 2023-12-31 | $75.23 Million | +1.00% |
| 2022-12-31 | $74.48 Million | -37.85% |
| 2021-12-31 | $119.85 Million | -20.09% |
| 2020-12-31 | $149.97 Million | +21.51% |
| 2019-12-31 | $123.43 Million | +40.13% |
| 2018-12-31 | $88.08 Million | +219.25% |
| 2017-12-31 | $27.59 Million | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more